 | Up a level |
Ansen, S., Schultheis, A., Hellmich, M., Leenders, F., Zander, T., Michels, S., Brockmann, M., Stoelben, E., Groen, H., Timens, W., Buettner, R., Thomas, R. K., Perner, S. and Wolf, J. (2014). PD-L1 expression and genotype in Non-Small Cell Lung Cancer (NSCLC). Oncol. Res. Treat., 37. S. 5 - 7. BASEL: KARGER. ISSN 2296-5262
Castiglione, R., Ihle, M. A., Heydt, C., Alidousty, C., Schultheis, A., Merkelbach-Bruse, S., Hermsen, M., Buettner, R. and Franchi, A. (2017). Molecular characterisation of sinunasal carcinomas. Virchows Arch., 471. S. S150 - 1. NEW YORK: SPRINGER. ISSN 1432-2307
Eisert, A., Scheffler, M., Michels, S., Schultheis, A., Koenig, K., Merkelbach-Bruse, S., Serke, M., Ko, Y. -D, Gerigk, U., Heukamp, L. C., Buettner, R. and Wolf, J. (2014). Genetic variability and clinical presentation of patients with non-small cell lung cancer (NSCLC) harboring MET-amplifications. Oncol. Res. Treat., 37. S. 8 - 9. BASEL: KARGER. ISSN 2296-5262
Eisert, A. K., Scheffler, M., Michels, S., Schultheis, A., Koenig, K., Merkelbach-Bruse, S., Serke, M., Ko, Y., Gerigk, U., Geist, T., Heukamp, L. C., Buettner, R. and Wolf, J. (2014). GENETIC VARIABILITY AND CLINICAL PRESENTATION OF PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING MET-AMPLIFICATIONS. Ann. Oncol., 25. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Gautschi, O., Pall, G., Schultheis, A., Keller, F. Aebersold, Gardizi, M., Heuckmann, J., Merkelbach-Bruse, S., Diebold, J., Wolf, J. and Heukamp, L. (2014). LUNG ADENOCARCINOMA WITH RET FUSION: EARLY EXPERIENCE WITH DIAGNOSIS AND TARGETED THERAPY. J. Thorac. Oncol., 9 (4). S. S38 - 1. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1556-1380
Michels, S., Gardizi, M., Schultheis, A., Scheffler, M., Karachaliou, N., Teixido, C., Heukamp, L., Merkelbach-Bruse, S., Thurat, M., Nogova, L., Bos, M., Mattonet, C., Grohe, C., Sebastian, M., Thomas, M., Reck, M., Stahel, R., Pirker, R., Zoechbauer-Mueller, S., Groen, H., Dingemanns, A. -M, Smit, E., Thomas, R., Buettner, R., Massuti, B., Rosell, R. and Wolf, J. (2014). EUCROSS: A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262
Michels, S., Schultheis, A., Scheffler, M., Rosner, T., Merkelbach-Bruse, S., Heukamp, L., Engel-Riedel, W., Serke, M., Krueger, S., Benedikter, J., Gerigk, U., Schulte, W., Draube, A., Ko, Y. D., Buettner, R. and Wolf, J. (2014). RET rearrangement in adenocarcinoma of the lung. Oncol. Res. Treat., 37. S. 6 - 7. BASEL: KARGER. ISSN 2296-5262
Scheffler, M., Schultheis, A., Michels, S., Teixido, C., Hartmann, W., Merkelbach-Bruse, S., Sebastian, M., Serke, M., Kropf-Sanchen, C., Wittersheim, M., Puetz, K., Binot, E., Schildhaus, H. -U., Heukamp, L. C., Rosell, R., Buettner, R. and Wolf, J. (2014). ROS1 rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predicitve impact and genetic variability. Oncol. Res. Treat., 37. S. 66 - 67. BASEL: KARGER. ISSN 2296-5262